Market Overview

ProQR Therapeutics N.V. Begins Enrollment for PQ-010-001 Study


ProQR Therapeutics N.V.(PRQR) says enrollment has started in study PQ-010-001, a global Phase 1b clinical study of QR-010, an investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the DF508 mutation.

Posted-In: News FDA Press Releases


Related Articles (PRQR)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

USD/JPY Moves Up

UPDATE: Ashoford Trust Announces Plans To Sell Select-Service Hotel